More Education Needed on Breast Density and Screening Choices
Being a resident in a state with a dense breast notification law does not appear to help women know more about breast density.
Breast Cancer
Multidisciplinary Approach Maintains, Restores Fertility in Female Patients With Cancer
A report on oncofertility identifies the optimal multidisciplinary team for assuring that young patients with cancer can preserve their fertility and the options available to them for family building.
Mammos May Not Benefit Elderly Women With Chronic Illness
Risk for death from other causes much higher than risk for breast cancer death with increasing comorbidity, age
Type and Timing of Menopausal Hormone Therapy May Affect Breast Cancer Risk
Use of menopausal hormonal therapy for 5 years around the start of menopause may be associated with increased risk for breast cancer.
USPSTF Recommends Medications to Reduce Risk for Primary Breast Cancer
The USPSTF recommends that physicians offer risk-reducing medications to women at greater risk for breast cancer and lower risk for adverse medication effects.
FDA Advises Including Men in Breast Cancer Clinical Trials
Draft guidance that men be included in breast cancer trials was issued by the FDA on August 26, 2019.
Previously Hidden FDA Data Reveal a Multitude of Adverse Events Linked to Breast Implants
Why were adverse events reported through an alternative reporting channel as opposed to a more transparent means?
Ibrance Approved to Treat Male Patients With Breast Cancer
The FDA has expanded the indication of Ibrance (palbociclib; Pfizer) for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in male patients, in combination with an aromatase inhibitor or fulvestrant.
Mammography Screening Rates Increase After Elimination of Cost Sharing
The elimination of cost sharing for screening mammography is associated with increased screening rates.
FDA Approves Lynparza to Treat Breast Cancer Caused by BRCA Mutation
The FDA has approved Lynparza to treat metastatic breast cancer caused by a BRCA gene mutation.
Next post in Medicine
